Genentech’s Esbriet a Breakthrough Therapy for interstitial lung disease

The FDA has granted Breakthrough Therapy Designation to Roche (OTCQX:RHHBY) unit Genentech’s Esbriet (pirfenidone) for adults with unclassifiable interstitial lung disease (uILD).

Breakthrough Therapy status provides for more intensive guidance from the FDA on development, the involvement of more senior agency personnel and a rolling review of the marketing application.

https://seekingalpha.com/news/3547893-genentech-s-esbriet-breakthrough-therapy-for-interstitial-lung-disease